Allogene Therapeutics (ALLO) Q4 2025 earnings review
Disciplined Cash Burn Sets Up Make-or-Break 2026 Catalysts
Allogene closed 2025 with a significantly decelerating cash burn, dropping its Q4 net loss by 35% YoY to $38.8M. By aggressively slashing R&D and manufacturing expenses, the company extended its cash runway into Q1 2028. This capital preservation is critical, as the company is entirely reliant on two major binary events in H1 2026: the April futility analysis for cema-cel in Large B-Cell Lymphoma and the June proof-of-concept data for ALLO-329 in autoimmune disease. With ALLO-316 officially sidelined pending a partnership, Allogene has placed all its chips on these two readouts.
🐂 Bull Case
Ending Q4 with $258.3M in cash and a runway into Q1 2028 (aided by a $23.7M escrow return in early 2026) thoroughly de-risks funding concerns ahead of the company's major 2026 clinical milestones.
Management has drawn a clear line for the April 2026 ALPHA3 futility analysis: a 25-30% improvement in MRD clearance over observation. Hitting this mark could validate allogeneic CAR T in a first-line consolidation setting.
🐻 Bear Case
With the solid tumor program (ALLO-316) parked for partnering, valuation rests entirely on 12-patient cohorts in the ALPHA3 trial and a handful of patients in the ALLO-329 trial.
ALLO-329 aims to eliminate traditional lymphodepletion. If this unproven Dagger technology fails to induce adequate CAR T expansion, the autoimmune strategy will falter against entrenched autologous competitors.
⚖️ Verdict: ⚪
Neutral. The company has executed masterfully on cost controls, ensuring survival through its critical data readouts. However, the investment thesis remains highly speculative and entirely dependent on unblinded data from very small patient cohorts arriving in Q2 2026.
Key Themes
Aggressive Cost Reductions Lengthen Runway
Allogene is demonstrating stable, disciplined execution on expenses. Total operating expenses dropped from $60.5M in 24Q4 to $42.4M in 25Q4. Research and development expenses decelerated heavily, dropping from $45.0M a year ago to $28.6M. This was driven by targeted reductions in manufacturing operations and focusing solely on ALPHA3 and RESOLUTION trials, extending the cash runway from 2H 2027 to Q1 2028.
ALPHA3 Futility Analysis in April 2026
The pivotal Phase 2 ALPHA3 trial for cema-cel is the primary valuation driver. The trial aims to prove that early, MRD-guided consolidation can prevent relapse in LBCL. The April 2026 interim futility analysis will compare MRD clearance in 12 patients receiving cema-cel versus 12 on observation. Management stated that a 25-30% improvement in clearance could indicate clinical proof-of-concept.
Dagger Technology and ALLO-329 in Autoimmune
ALLO-329 utilizes proprietary Dagger technology, a built-in targeted lymphodepletion mechanism that selectively eliminates activated CD70-positive T cells. This allows the trial to evaluate dosing without standard cytotoxic lymphodepletion. Initial proof-of-concept data from the RESOLUTION trial, utilizing an exceptionally low dose of 20 million CAR T cells, is expected in June 2026. If successful, it solves a major tolerability hurdle in the rheumatology space.
Deprioritization of Solid Tumor Program (ALLO-316)
Despite completing Phase 1b enrollment and demonstrating some clinical activity in renal cell carcinoma, ALLO-316 has been shelved internally. The company is exploring partnering opportunities to advance the asset. This indicates severe capital constraints forcing the company to abandon a potentially lucrative solid tumor vertical to protect its core hematology and autoimmune bets.
Small N for Make-or-Break Catalysts
The highly anticipated April 2026 ALPHA3 data relies on just 12 patients per cohort. While MRD conversion is a powerful biomarker, utilizing such a small sample size introduces significant volatility risk. Any patient anomalies or dropouts could skew the 25-30% target delta required to avoid a futility stop.
Other KPIs
Decelerating burn rate stabilized the balance sheet. The balance fell $114.8M across FY25 (from $373.1M in FY24), representing an average quarterly burn of roughly $28.7M. The company will also receive a $23.7M escrow return in February 2026 related to a favorable arbitration outcome.
Reversing the aggressive spending of the prior year. FY25 net loss of $190.9M is a massive improvement compared to the $257.6M loss in FY24. This was primarily driven by a $42.1M reduction in R&D expenses.
Guidance
Stable. This guidance aligns exactly with the estimated ~$150M cash burn guided and executed throughout 2025. It demonstrates that the company's cost structure has found a floor and will be maintained steadily through the critical mid-2026 data readouts.
Stable. The $210M forecast (which includes ~$35M in non-cash stock-based compensation) is effectively flat YoY compared to the $209.3M in total operating expenses reported for FY25.
Accelerating/Improving. This is a crucial update, extending the previously guided runway of 'second half of 2027' by at least a quarter, heavily supported by the $23.7M escrow return and opportunistic ATM usage.
Key Questions
ALPHA3 Futility Margins
If the MRD clearance delta in the April 2026 futility analysis comes in exactly at the low end of your expectations or slightly below (e.g., 20%), will the trial be halted, or is there flexibility to expand the cohort?
ALLO-329 Efficacy Threshold
For the June 2026 proof-of-concept update in autoimmune disease, what specific clinical or symptomatic responses are you expecting to see alongside the biomarker data from the 20 million cell dose cohort?
ALLO-316 Partnership Timeline
With ALLO-316 effectively paused internally, how long are you willing to wait to secure a partnership before the asset's Phase 1b data loses its competitive relevance in the rapidly evolving solid tumor space?